Phase I/II trial assesses the safety of a dual VEGFR peptide vaccine in NF2-related schwannomatosis, highlighting an immunotherapy avenue for progressive tumors.
The humanized antivascular endothelial growth factor (VEGF) antibody bevacizumab (Bev) is efficacious for the treatment of NF2-related schwannomatosis (NF2), previously known as neurofibromatosis type 2. This study evaluated the safety and efficacy of a VEGF receptor (VEGFR) vaccine containing VEGFR1 and VEGFR2 peptides in patients with NF2 with progressive schwannomas (jRCTs031180184).
No takes yet. Share an insight, caveat, or question.
Tamura et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: